Ankle-Brachial Index and Peripheral Arterial Disease

Zusammenfassung

Patienten mit peripherer Arteriosklerose und insbesondere solche mit Claudicatio intermittens haben ein deutlich erhöhtes Risiko für kardio- und zerebrovaskuläre Morbidität und Mortalität. Das Schicksal dieser Patienten wird weniger durch lokale Komplikationen im Bein als durch systemische Komplikationen im Bereich der koronaren und der zerebralen Gefäße geprägt. Durch Untersuchungen in der KORA-Studie 2004/2005 (F3), einer Nachuntersuchung der Teilnehmer der MONICA-Studie 1994/1995 (S3), werden wir versuchen, biochemische sowie genetische Risikofaktoren für die periphere arterielle Verschlusskrankheit zu identifizieren. Einer der uns besonders interessierenden Kandidaten ist das antiatherogene Apolipoprotein A-IV.

Abstract

Patients with peripheral arterial disease including those with intermittent claudication have a high risk for cardiovascular and cerebrovascular morbidity and mortality. The outcome of patients with intermittent claudication is less limited by local complications in the leg than by the systemic complications of coronary and cerebral vessels. About 30 % of these patients will die within 5 years, three-quarters of them due to vascular events. Analyses using data of the KORA Study 2004/2005 (F3), a follow-up examination of the participants of the MONICA Survey 1994/95 (S3), will try to identify biochemical as well as genetic risk factors for peripheral arterial disease. The anti-atherogenic apolipoprotein A-IV will be one of our candidates of interest.

Periphere Atherosklerose - Claudicatio intermittens - KORA - Genetik - Apolipoprotein A-IV

Peripheral arterial disease - intermittent claudication - KORA - genetics - apolipoprotein A-IV

References

• 1 Management of peripheral arterial disease (PAD) . TransAtlantic Inter-Society Consensus (TASC).  Int Angiol. 2000;  19 (Suppl 1) 1-304
• 2 Kazamias T M, Gander M P, Franklin D L. et al . Blood pressure measurement with Doppler ultrasonic flowmeter.  J Appl Physiol. 1971;  30 585-588
• 3 Stegall H F, Kardon M B, Kemmerer W T. Indirect measurment of arterial blood pressure by Doppler ultrasonic sphygmomanometry.  J Appl Physiol. 1968;  25 793-798
• 4 Fowkes F G, Housley E, Macintyre C C. et al . Variability of ankle and brachial systolic pressures in the measurement of atherosclerotic peripheral arterial disease.  J Epidemiol Community Health. 1988;  42 128-133
• 5 Schroll M, Munck O. Estimation of peripheral arteriosclerotic disease by ankle blood pressure measurements in a population study of 60-year-old men and women.  J Chronic Dis. 1981;  34 261-269
• 6 Laing S, Greenhalgh R M. The detection and progression of asymptomatic peripheral arterial disease.  Br J Surg. 1983;  70 628-630
• 7 Carter S A. Indirect systolic pressures and pulse waves in arterial occlusive diseases of the lower extremities.  Circulation. 1968;  37 624-637
• 8 Leng G C, Fowkes F G. The Edinburgh Claudication Questionnaire: an improved version of the WHO/Rose Questionnaire for use in epidemiological surveys.  J Clin Epidemiol. 1992;  45 1101-1109
• 9 Hiatt W R, Hoag S, Hamman R F. Effect of diagnostic criteria on the prevalence of peripheral arterial disease. The San Luis Valley Diabetes Study.  Circulation. 1995;  91 1472-1479
• 10 Diehm C, Schuster A, Allenberg J R. et al . High prevalence of peripheral arterial disease and co-morbidity in 6880 primary care patients: cross-sectional study.  Atherosclerosis. 2004;  172 95-105
• 11 Meijer W T, Hoes A W, Rutgers D. et al . Peripheral arterial disease in the elderly - The Rotterdam study.  Arterioscler Thromb Vasc Biol. 1998;  18 185-192
• 12 Murabito J M, D’Agostino R B, Silbershatz H. et al . Intermittent claudication. A risk profile from The Framingham Heart Study.  Circulation. 1997;  96 44-49
• 13 Hughson W G, Mann J I, Garrod A. Intermittent claudication: prevalence and risk factors.  BMJ. 1978;  1 1379-1381
• 14 Hertzer N R, Beven E G, Young J R. et al . Coronary artery disease in peripheral vascular patients. A classification of 1000 coronary angiograms and results of surgical management.  Ann Surg. 1984;  199 223-233
• 15 Crawford E S, Bomberger R A, Glaeser D H. et al . Aortoiliac occlusive disease: factors influencing survival and function following reconstructive operation over a twenty-five-year period.  Surgery. 1981;  90 1055-1067
• 16 Aronow W S, Ahn C. Prevalence of coexistence of coronary artery disease, peripheral arterial disease, and atherothrombotic brain infarction in men and women > or = 62 years of age.  Am J Cardiol. 1994;  74 64-65
• 17 Murabito J M, Evans J C, Nieto K. et al . Prevalence and clinical correlates of peripheral arterial disease in the Framingham Offspring Study.  Am Heart J. 2002;  143 961-965
• 18 Jönsson B, Skau T. Ankle-brachial index and mortality in a cohort of questionnaire recorded leg pain on walking.  Eur J Vasc Endovasc Surg. 2002;  24 405-410
• 19 Jager A, Kostense P J, Ruhe H G. et al . Microalbuminuria and peripheral arterial disease are independent predictors of cardiovascular and all-cause mortality, especially among hypertensive subjects: five-year follow-up of the Hoorn Study.  Arterioscler Thromb Vasc Biol. 1999;  19 617-624
• 20 Muluk S C, Muluk V S, Kelley M E. et al . Outcome events in patients with claudication: a 15-year study in 2777 patients.  J Vasc Surg. 2001;  33 251-257
• 21 Labs K H, Dormandy J A, Jaeger K A. et al . Trans-atlantic conference on clinical trial guidelines in PAOD (Peripheral arterial occlusive disease) clinical trial methodology.  Eur J Vasc Endovasc Surg. 1999;  18 253-265
• 22 Utermann G, Beisiegel U. Apolipoprotein A-IV: a protein occurring in human mesenteric lymph chylomicrons and free in plasma. solation and quantification.  Eur J Biochem. 1979;  99 333-343
• 23 Stein O, Stein Y, Lefevre M. et al . The role of apolipoprotein A-IV in reverse cholesterol transport studied with cultured cells and liposomes derived from another analog of phosphatidylcholine.  Biochim Biophys Acta. 1986;  878 7-13
• 24 Steinmetz A, Barbaras R, Ghalim N. et al . Human apolipoprotein A-IV binds to apolipoprotein A-I/A-II receptor sites and promotes cholesterol efflux from adipose cells.  J Biol Chem. 1990;  265 7859-7863
• 25 Steinmetz A, Utermann G. Activation of lecithin: cholesterol acyltransferase by human apolipoprotein A-IV.  J Biol Chem. 1985;  260 2258-2264
• 26 Chen C H, Albers J J. Activation of lecithin: cholesterol acyltransferase by apolipoproteins E-2, E-3 and A-IV isolated from human plasma.  Biochim Biophys Acta. 1985;  836 279-285
• 27 Goldberg I J, Scheraldi C A, Yacoub L K. et al . Lipoprotein ApoC-II activation of lipoprotein lipase. Modulation by apolipoprotein A-IV.  J Biol Chem. 1990;  265 4266-4272
• 28 Guyard-Dangremont V, Lagrost L, Gambert P. Comparative effects of purified apolipoproteins A-I, A-II, and A- IV on cholesteryl ester transfer protein activity.  J Lipid Res. 1994;  35 982-992
• 29 Qin X F, Swertfeger D K, Zheng S Q. et al . Apolipoprotein AIV: A potent endogenous inhibitor of lipid oxidation.  Am J Physiol. 1998;  274 H1836-H1840
• 30 Ostos M A, Conconi M, Vergnes L. et al . Antioxidative and antiatherosclerotic effects of human apolipoprotein A-IV in apolipoprotein E-deficient mice.  Arterioscler Thromb Vasc Biol. 2001;  21 1023-1028
• 31 Drazen D L, Woods S C. Peripheral signals in the control of satiety and hunger.  Curr Opin Clin Nutr Metab Care. 2003;  6 621-629
• 32 Lefevre M, Lovejoy J C, DeFelice S M. et al . Common apolipoprotein A-IV variants are associated with differences in body mass index levels and percentage body fat.  Int J Obes Relat Metab Disord. 2000;  24 945-953
• 33 Fiegenbaum M, Hutz M H. Further evidence for the association between obesity-related traits and the apolipoprotein A-IV gene.  Int J Obes Relat Metab Disord. 2003;  27 484-490
• 34 Lingenhel A, Eder C, Zwiauer K. et al . Decrease of plasma apolipoprotein A-IV during weight reduction in obese adolescents on a low fat diet.  Int J Obes. 2004;  28 1509-1513
• 35 Duverger N, Tremp G, Caillaud J M. et al . Protection against atherogenesis in mice mediated by human apolipoprotein A-IV.  Science. 1996;  273 966-968
• 36 Cohen R D, Castellani L W, Qiao J H. et al . Reduced aortic lesions and elevated high density lipoprotein levels in transgenic mice overexpressing mouse apolipoprotein A-IV.  J Clin Invest. 1997;  99 1906-1916
• 37 Kronenberg F, Stühlinger M, Trenkwalder E. et al . Low apolipoprotein A-IV plasma concentrations in men with coronary artery disease.  J Am Coll Cardiol. 2000;  36 751-757
• 38 Duverger N, Ghalim N, Ailhaud G. et al . Characterization of apoA-IV-containing lipoprotein particles isolated from human plasma and interstitial fluid.  Arterioscler Thromb. 1993;  13 126-132
• 39 Von Eckardstein A, Huang Y, Wu S. et al . Lipoproteins containing apolipoprotein A-IV but not apolipoprotein A-I take up and esterify cell-derived cholesterol in plasma.  Arterioscler Thromb Vasc Biol. 1995;  15 1755-1763
• 40 Kronenberg F, Kuen E, Ritz E. et al . Apolipoprotein A-IV serum concentrations are elevated in mild and moderate renal failure.  J Am Soc Nephrol. 2002;  13 461-469
• 41 Ezeh B, Haiman M, Alber H F. et al . Plasma distribution of apoA-IV in patients with coronary artery disease and healthy controls.  J Lipid Res. 2003;  44 1523-1529
• 42 Wong W M, Hawe E, Li L K. et al . Apolipoprotein AIV gene variant S347 is associated with increased risk of coronary heart disease and lower plasma apolipoprotein AIV levels.  Circ Res. 2003;  92 969-975